Schnitzler syndrome

Lore & Background

Schnitzler syndrome was first described in 1972 by French dermatologist Liliane Schnitzler. The condition typically presents around age 55 with recurrent hives on the torso and limbs, often accompanied by fever, joint and bone pain, fatigue, and weight loss. Blood tests reveal a monoclonal gammopathy, almost always of the IgM type with κ light chains, and signs of inflammation such as elevated white blood cell count and C-reactive protein. Diagnostic criteria were established in 2001 (Lipsker criteria) and refined in 2012 (Strasbourg criteria), requiring the presence of hives and monoclonal IgM or IgG along with additional symptoms.

Reader's Guide

Schnitzler syndrome is significant as a rare autoinflammatory disorder that bridges dermatology, rheumatology, and hematology. Its pathogenesis remains elusive, as noted in a 2024 review, with the relationship between autoinflammatory features and monoclonal gammopathy still unresolved. The condition is highly responsive to anakinra, an interleukin-1 inhibitor, which induces rapid remission but is not curative; symptoms recur upon cessation. Around 15–20% of patients develop lymphoproliferative complications, most commonly Waldenström's macroglobulinemia. Despite this, life expectancy is not substantially reduced. The syndrome's rarity—748 reported cases by December 2024—and its unique clinical profile make it a key example of late-onset autoinflammatory disease, with ongoing research into its pathophysiology and optimal management.

Did You Know?

• Schnitzler syndrome is named after French dermatologist Liliane Schnitzler, who first described it in 1972.
• Around 15–20% of people with Schnitzler syndrome develop a lymphoproliferative disorder, most commonly Waldenström's macroglobulinemia.
• Anakinra is so effective that lack of response to it may prompt reconsideration of the diagnosis.
• The most recent comprehensive reviews estimate around 200–300 cases reported in the medical literature.